Page 3 - John Mafi News Today

It’s not clear just how much vitamin C and D supplements you need for a healthy immune system — and if you need the supplements at all. Here’s what...

The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for

The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for

To qualify for Leqembi, patients must undergo a PET scan that looks for amyloid plaques, the protein clumps that clog the brains of many Alzheimer’s patients.

The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for

Although Leqembi can help treat Alzheimer's disease, there are risks, as well as cost and accessibility issues that may pose as concerns.

Highlights from the San Francisco Chronicle, Fortune, CNN and others.

The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors at risk of Alzheimer’s, experts say.

The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for many of the lower-income seniors most likely to suffer from dementia.

Medicare could shell out more than $100,000 a year per patient to cover the drug and the complex scans and tests needed to monitor its potentially lethal risks for patients.